{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Complete Response"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Partial Response"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Stable Disease"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Progressive Disease"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Objective Response was investigator-assessed based on the Response Evaluation Criteria In Solid Tumors version 1.1 \\[RECIST 1.1\\] criteria. The best overall response was reported for each participant.","groups":[{"description":"Tisotumab vedotin was administered as an intravenous (IV) infusion on Day 1 of each 21-day cycle (once every 3 weeks). The trial ran until the investigator determined that the participant was no longer benefiting from treatment (ie, disease progression or unacceptable toxicity had occurred), the trial was terminated by the sponsor, or the participant withdrew consent. Each participant received the same dose that they were exposed to in the previous base trial.","id":"OG000","title":"Tisotumab Vedotin"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Day 1 to Week 24 plus 30 days","title":"Objective Response Rate","type":"SECONDARY","unitOfMeasure":"Participants"}